Forceps | Cryoprobe | p-value | |
Patient characteristics | |||
Patients | 297 | 296 | |
Age yrs | 65.3±9.9 | 64.8±10.3 | 0.55 |
Male | 207 (69.6) | 217 (73.4) | 0.36 |
Body height cm | 170.9±8.5 | 170.2±8.9 | 0.33 |
Body weight kg | 74.3±14.7 | 72.3±15.0 | 0.10 |
Aspirin 100 mg·day−1 | 25 (8.42) | 27 (9.12) | 0.77 |
Clopidogrel 75 mg·day−1 | 1 (0.34) | 4 (1.35) | 0.22 |
General anaesthesia | 134 (45.1) | 136 (45.9) | 0.87 |
Rigid bronchoscopy | 133 (44.8) | 136 (45.9) | 0.80 |
PT % | 95.1±16.6 | 94.7±16.2 | 0.77 |
PTT s | 29.8±4.6 | 29.5±4.6 | 0.43 |
Thrombocyte count ×103 cells·μL−1 | 331.6±130.9 | 331.0±118.8 | 0.95 |
NSCLC | 192 | 196 | 0.73 |
SCLC | 62 | 56 | 0.61 |
Other malignant disease | 27 | 30 | 0.68 |
Other disease | 16 | 14 | 0.85 |
Distribution of the biopsy sites | |||
Trachea | 18 | 16 | 0.40 |
Main bronchi | 62 | 57 | |
Lobe bronchi and intermediate bronchus | 156 | 175 | |
Segmental bronchi | 61 | 48 | |
Lesions in patients with malignancy | |||
Exophytic | 190 | 183 | 0.49 |
Submucosal | 91 | 99 |
Data are presented as n, n (%) or mean±sd, unless otherwise stated. None of the values differed significantly between the two biopsy groups. PT: prothrombin time; PTT: partial thromboplastin time; NSCLC: nonsmall cell lung cancer; SCLC: small cell lung cancer.